The intellectual property and outsourcing in China, while minimizing risk and maximize return on investment – Aarkstore Enterprise

Posted on April 5, 2010, 5:12 am

Aarkstore announce a new report on “Intellectual Property and Outsourcing in China: while minimizing risk and maximize return on investment” through his vast collection of market research report. The intellectual property and outsourcing China, while minimizing risk and maximize return on investment in pharmaceutical outsourcing industry in China has experienced 35% year on year growth in recent years. Increasingly, the offering sophisticated services multinational CRO CMO is challenged by improving Chinese players import expertise Western experience and business models on this fast growing market. However, there are still wide variations in service quality and capacity of Canadian suppliers for subcontracting and many pharmaceutical and biotech companies in western markets are still reluctant to transfer part of the process of drug development for China. Their concerns largely stem from issues about intellectual property rights (IPR) infringements of copyright and counterfeiting. Both in business and government, this weakness has been recognized and several important changes have been made to the Chinese law on patents, while that service providers have also sought to improve their processes for IPR protection and service standards. However, major differences in the safety standards of IPR protection and service capacity are among the national players. “The intellectual property and outsourcing in China “is a new report examines the industry growing pharmaceutical outsourcing market in China to discover how large pharmaceutical companies, small pharmaceutical and biotechnology can more efficiently utilize provision of services and capabilities of the country. It examines the latest trends and outsourcing services at all stages of drug discovery and profiles of the ROC national leader / CMOS. This report presents a thorough investigation of the changing landscape of IPR protection in China and analyzes the strategies that can reduce the risk of infringement. Case studies are used to illustrate the success of recent partnerships CRO CMO with Western companies and the main criteria for selection of appropriate service providers are also identified. Some key findings of this report. . . • China is the most attractive destination in the world for Pharma outsourcing based on an analysis of pools of patients, profitability, regulatory conditions, available expertise and infrastructure. • There were 694,153 patent applications in China in 2007, a CAGR of 22 years. 5% on the number of applications in 2003 (308,487). At this rate, China will be the world’s largest patent court filing in 2012. • service capabilities in China are strong, with large-scale medicinal chemistry services currently available from 26 CROs. The services include structure-based rational drug design, structure-activityrelationship (SAR) activity base optimization / power, and optimization of pharmacological properties of lead compounds. • In the next 3 to 5 years, the service capabilities of multiple service providers based in China are developing rapidly and changing the risk profile of IP. Currently, the domestic industry is highly skilled in large scale manufacturing, but relatively low in the preclinical and clinical development, and that the capacity of providers to increase the need for effective verification protocols for the protection of intellectual property will intensify. • The market will experience strong growth this year around 35% year on year to 2011. During this period, the investment industry is likely in the targeting, identification and validation capabilities. Top reasons to order your copy today • Understand how major pharmaceutical companies, pharmaceutical and small biotech companies may benefit from the Chinese pharmaceutical market with the analysis of this report the number of companies involved, the levels maturity of the industry and existing / projected capabilities offer service. • Assess risk factors associated with outsourcing decisions and measure the ability of China-based CROs and CMOS with consideration of the report of each class of service and key selection criteria of the company most appropriate, including the protocols of IPR protection, quality of service / capacity, cost and geographical location. • Understand how the environment of IPR protection in China is changing in evaluating the latest regulatory developments and trends in patent applications for national and multinational companies, in addition to market forecasts in this report to the growth of outsourcing industry by 2015. • Determine how IPR protection varies according to each stage of R & D and use case studies of partnerships between Chinese CROs / CMOS, and Western companies to measure the success of efforts years. The main issues discussed in this report. . . • variable service offerings. Many Chinese pharmaceutical companies that have manufacturing skills API only offer their services on a seasonal basis. They are not providers of CMO professional service offerings are largely dependent on levels of spare production capacity. • Human Services inflated. While many CROs / CMOS claim a broad scope of services to attract business, their actual powers are limited to service only one or two areas. More precisely, the scientific staff often lack sufficient experience, training and guidelines on deliverability. • Lack of system of IPR protection. IPR protection is no longer a serious problem among suppliers of high quality service, but may still be low in the lower-tier national firms and those operating in rural areas. • cases of IPR infringement and counterfeiting of medicines: Counterfeit drugs are still a real problem and most cases of IPR infringement are related to the trademark / copyright violations. However, there was no breach of a pharmaceutical or biotech Western intellectual property rights by a Chinese company in collaboration subcontracting. Answers to your questions. . . • How China compared to other outsourcing destinations? • What are the services offered by the CRO and CMO industry in China? • What are the benefits of outsourcing various stages of R & D by the large / small pharmaceutical and biotech companies? • What are the government’s development priorities for the industry? • How has supported the growth of the medical infrastructure specific to the area of outsourcing and the trend continue? • What is the largest sector of China pharmaceutical outsourcing industry in terms of number of companies and the strength of their services? • Who are the key Chinese players in contract research and in what areas do they specialize? • What are the multinational companies have outsourced their projects in China? • What are the actions that the government is taking to strengthen IPR protection? For more information, please visit: http://www. aarkstore. com/reports/Intellectual-Property-and-Outsourcing-in-China-Minimizing-risk-whilst-maximizing-return-on-investment-14225. htmlOr mail us at press @ aarkstore. com or call +919272852585 Special offer until December 31, 2009